Key considerations for shortening your CAR-T manufacturing process [WEBINAR]

For more information, visit: www.miltenyibi... In this webinar, we explore a 1-week automated manufacturing process for autologous CAR-T cell therapy using the CliniMACS Prodigy® Platform. Key discussions include reducing vein-to-vein time, optimizing CAR-T production, and enhancing shelf life. The process efficiently produces potent CAR-T cells, supported by in vitro and in vivo studies, to improve outcomes for relapsed or refractory B-cell malignancies.
Miltenyi Biotec is a global leader innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to sets industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.